Up-to-date List of Metoprolol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Metoprolol Medical Research Studies

RankStatusStudy
1 Recruiting Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function
Conditions: Hypertension;   Female Sexual Dysfunction
Interventions: Drug: nebivolol and Metoprolol succinate;   Drug: Metoprolol succinate and nebivolol
Outcome Measures: Change in FSF and CSFQ, two validated questionnaires for assessment of sexual function.;   The effects of nebivolol and Metoprolol on sexual function and to compare the effects of both drugs on vitality, work and life performance, and work and life satisfaction.
2 Recruiting Influence of CPB and Mini CPB to the Absorption of the Metoprolol
Condition: Drug Absorption
Intervention: Drug: blood concentration of Metoprolol
Outcome Measures: absorbtion of the Metoprolol;   atrial fibrillation
3 Not yet recruiting A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants
Condition: Healthy
Interventions: Drug: Metoprolol tartrate immediate-release (Metoprolol IR);   Drug: JNJ-54452840;   Drug: Placebo
Outcome Measures: Exercise Heart Rate;   Exercise Blood Pressure
4 Recruiting Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: Metoprolol;   Drug: Diltiazem
Outcome Measures: Conversion to sinus rhythm;   Heart rate control;   Home discharges from Emergency Department (ED);   Total hospital cost;   Rehospitalization for Atrial Fibrillation
5 Not yet recruiting Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Condition: Vasovagal Syncope
Interventions: Drug: Metoprolol;   Drug: Matching Placebo
Outcome Measures: The primary outcome measure will be the proportion of patients having at least one syncope recurrence.;   A secondary outcome will be the time between the first and second syncope recurrences.;   A secondary outcome will be the frequency of syncopal spells.;   A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary Presyncope Scale);   A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL.
6 Not yet recruiting Comparison of Efficacy of Ivabradine Versus Metoprolol
Condition: Coronary Artery Disease
Intervention: Drug: Ivabradine and Metoprolol
Outcome Measures: Heart rate of patient before CT coronary;   safety and side effect of Metoprolol and Ivabradine
7 Recruiting Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: bucindolol hydrochloride;   Drug: Metoprolol succinate
Outcome Measures: Time to first event of symptomatic atrial fibrillation/atrial flutter (AF/AFL) or all cause mortality (ACM) during the 24-week Follow-up Period after conversion to stable sinus rhythm (SR);   Time to first event of AF/AFL (i.e., symptomatic or asymptomatic) or ACM during the 24-week Follow-up Period;   Proportion of patients during the 24-week Follow-up Period with ventricular tachycardia (VT), ventricular fibrillation (VF), or symptomatic supraventricular tachycardia (SVT);   Total number of hospitalization (all-cause) days per patient during the Total Study Period;   Time to first event of ACM or heart failure (HF) hospitalization (as assessed by the Investigator) during the Total Study Period;   Proportion of patients who have AF on ECG at the end of the study who demonstrate ventricular response rate (VRR) control
8 Recruiting A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
Condition: Myocardial Ischemia
Interventions: Drug: Metoprolol;   Drug: Esmolol;   Drug: Placebo
Outcome Measures: Our objective is to clarify if Metoprolol, in a dose range used for perioperative cardiac protection, decreases anesthetic requirement.;   Administration of esmolol, a short-acting beta-receptor antagonist, might reduce the actual anesthetic requirement.
9 Recruiting Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
Conditions: Cirrhosis;   Cirrhotic Cardiomyopathy;   Cardiac Remodeling
Interventions: Drug: Metoprolol succinate;   Drug: placebo
Outcome Measures: Improvement of systolic function;   Improvement in left ventricular diastolic function;   Renal function;   Serum level of BNP, catecholamines, plasmatic renin activity;   Mortality;   Quality of life;   Electrophysiologic modifications
10 Unknown  Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Metoprolol
Outcome Measures: Difference in airway reactivity after treatment with Metoprolol compared to placebo.;   Effect of formoterol on airway reactivity comparing Metoprolol with placebo.;   Borg-scores during provocation test;   Peak-flow measurements;   CCQ-scores;   Exacerbation rate and rescue medication use
11 Recruiting Sarpogrelate Drug Interaction
Conditions: Hypertension;   Peripheral Artery Disease
Interventions: Drug: Sarpogrelate pretreatment;   Drug: Sarpogrelate;   Drug: Metoprolol
Outcome Measures: Plasma concentration of Metoprolol and metabolites;   Blood pressure and pulse rate changes
12 Recruiting Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
Conditions: Peripheral Artery Disease;   Hypertension
Interventions: Drug: nebivolol;   Drug: Metoprolol succinate
Outcome Measures: Peak Walking Time;   Walking Impairment Questionnaire;   Ankle-brachial index;   markers of inflammation.;   Claudication Onset Time
13 Recruiting Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients
Condition: Hypertension
Interventions: Drug: Metoprolol succinate;   Drug: Nebivolol;   Drug: Hydrochlorothiazide;   Drug: DEFINITY®;   Procedure: Non-invasive measurement of Cardiac Output (CO);   Procedure: Flow mediated vasodilation;   Procedure: Endothelial cell collection;   Procedure: Microvascular perfusion assessment using Definity
Outcome Measures: Endothelial cell protein expression;   Microvascular blood flow;   Flow mediated dilation (FMD)
14 Recruiting PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
Conditions: Lung Cancer;   Atrial Fibrillation
Interventions: Drug: Metoprolol;   Drug: Losartan
Outcome Measures: Incidence of postoperative atrial fibrillation;   Evaluation of NT-proBNP in the days following the start of treatment and post surgery duration of hospital stay
15 Unknown  Combined Antihypertensive Therapy and Sexual Dysfunction
Conditions: Hypertension;   Sexual Dysfunction
Interventions: Drug: Felodipine add Irbesartan;   Drug: Felodipine add Metoprolol
Outcome Measures: Female Sexual Function Index (FSFI);   International Index of Erectile Function(IIEF);   Change of Systolic Blood Pressure in 2 Weeks;   Change of Systolic Blood Pressure in 4 Weeks;   Change of Systolic Blood Pressure in 8 Weeks;   Change of Systolic Blood Pressure in 12 Weeks;   Change of Systolic Blood Pressure in 24 Weeks;   Change of Systolic Blood Pressure in 48 Weeks;   Change of Diastolic Blood Pressure in 2 Weeks;   Change of Diastolic Blood Pressure in 4 Weeks;   Change of Diastolic Blood Pressure in 8 Weeks;   Change of Diastolic Blood Pressure in 12 Weeks;   Change of Diastolic Blood Pressure in 24 Weeks;   Change of Diastolic Blood Pressure in 48 Weeks;   Serum Estradiol in 24 Weeks;   Serum Estradiol in 48 Weeks;   Serum Testosterone in 24 Weeks;   Serum Testosterone in 48 Weeks;   Serum MDA in 24 Weeks;   Serum MDA in 48 Weeks;   Serum 8-OHdG in 24 Weeks;   Serum 8-OHdG in 48 Weeks;   Serum HNE in 24 Weeks;   Serum HNE in 48 Weeks
16 Unknown  Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Conditions: Endothelial Function;   Diabetes Mellitus;   Hypertension
Interventions: Drug: carvedilol;   Drug: Metoprolol extended release
Outcome Measure: Effect of Coreg CR compared to Toprol XL on endothelial function, vascular compliance, and parameters of oxidative stress from time of randomization to study drug termination
17 Recruiting A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
Condition: Heart Failure
Interventions: Drug: Extended-Release Carvedilol Sulfate;   Drug: Sustained-release Metoprolol Succinate
Outcome Measures: Change From Baseline in left ventricular ejection fraction(LVEF) by ultrasound cardiogram;   Change From Baseline in Left Ventricular End Systolic Volume Index;   Change From Baseline in Left Ventricular End Diastolic Volume Index;   Incidence of Hospitalizations From Exacerbation of Heart Failure;   Incidence of Hospitalizations From All Causes;   Incidence of Deaths From All Causes;   Change From Baseline in New York Heart Association(NYHA)classification
18 Unknown  Beta-Blocker Before Extubation
Condition: Myocardial Ischemia
Intervention: Drug: Metoprolol
Outcome Measures: The rate of ischemia as judged by ST segment analysis in the 4h following extubation;   Rate-pressure product following extubation;   Troponin T elevations, the incidence of cardiogenic edema, and the rate of reintubation;   Pro-BNP levels
19 Recruiting Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease
Condition: Chronic Kidney Disease
Intervention:
Outcome Measures: Primary Efficacy;   Secondary Efficacy
20 Unknown  Nebivolol and the Endothelin (ET)-1 System
Conditions: Prehypertension;   Hypertension
Interventions: Drug: Nebivolol;   Drug: Metoprolol;   Drug: Placebo
Outcome Measure: ET-1-mediated vasoconstrictor tone

These studies may lead to new treatments and are adding insight into Metoprolol etiology and treatment.

A major focus of Metoprolol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Metoprolol

privacy policy